Objective To assess whether the implementation of patient-controlled
analgesia (PCA) with piritramide using an automatic pump system under
routine conditions is effective to reduce pain in late abortion
inductions Design Prospective observational cohort study Setting
Patients requiring medically indicated abortion induction from 14 weeks
of pregnancy onwards between July 2019 and July 2020 at the department
of Obstetrics and Prenatal Medicine of the Bonn University Hospital in
Germany. Methods Evaluation of pain management after implementation of a
PCA system compared with previous nurse-controlled tramadol-based
standard under routine conditions. Patients answered a validated pain
questionnaire and requirement of rescue analgesics was assessed. Pain
intensity and satisfaction were measured on a ten-point numeric rating
scale. Main Outcome Measure Maximal pain intensity Results Forty
patients were included. Patients using Piritramide-PCA complained of
higher pain sores than those in the standard group (6.90 (± 2.34) vs.
4.83 (± 2.87), (p < 0.05)). In both groups the level of
satisfaction with the analgesia received was comparable (8.00 (± 2.45)
vs 7.67 (± 2.62), (p = 0.7)). Patients in the PCA group suffered more
nausea (63.2% vs 30% respectively, OR 4.0, 95% CI 1.05-15.20,
p<0.05) and expressed more the desire for more analgesic
support compared to the control group (OR 5.7 (1-33.25), p = 0.05).
Conclusion Women with abortion induction after 14 weeks of gestation
suffer from relevant severe pain, which requires adequate therapy.
However, addition of PCA does not seem to bring any advantage in
patients undergoing this procedure.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.